Top Markets
#1 DogBull DogBull +106.54%
#2 Siacoin Siacoin +51.52%
#3 ADO Protocol ADO Protocol +51.16%
#4 The Bitcoin Bull The Bitcoin Bull +43.15%
#5 MarsCoin MarsCoin +32.69%
#6 Glidr Glidr +25.97%
#7 龙虾 (Lobster) 龙虾 (Lobster) +25.93%
#8 UnifAI Network UnifAI Network +22.81%
#9 Ontology Gas Ontology Gas +19.72%
#10 Falcon Finance Falcon Finance +18.02%
Coin of the day
DogBull DogBull
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Jiangsu Recbio Technology Co., Ltd. Jiangsu Recbio Technology Co., Ltd.

Jiangsu Recbio Technology Co., Ltd.

2179
Classificação em ações #15657
Jiangsu Recbio Technology Co., Ltd. operates as a biotechnology company... Jiangsu Recbio Technology Co., Ltd. operates as a biotechnology company primarily engaged in the pioneering research, development, and eventual market introduction of subunit vaccines throughout the People's Republic of China. A significant portion of its pipeline is dedicated to combating human papillomavirus (HPV)-related diseases, including cervical cancer and genital warts. Its most advanced candidate, REC603, is a recombinant 9-valent HPV vaccine currently undergoing Phase III clinical trials. Additionally, two bivalent HPV vaccines, REC601 and REC602, are progressing through Phase I trials. Further early-stage development includes the quadrivalent REC604a and 9-valent REC604b recombinant HPV vaccines, both in preclinical stages. Beyond HPV, the company boasts a diverse pipeline addressing other infectious diseases. Its COVID-19 efforts include ReCOV, a recombinant vaccine candidate in Phase II/III trials, and the preclinical messenger RNA (mRNA) candidate, R520A. Other preclinical projects target various conditions, such as the recombinant shingles vaccine REC610, the virus-vectored adult tuberculosis vaccine REC607, and its recombinant counterpart REC606. Also in preclinical development are the recombinant quadrivalent influenza vaccine REC617 and the recombinant quadrivalent hand-foot-mouth disease vaccine REC605. Established in 2011, Recbio Technology maintains its headquarters in Taizhou, People's Republic of China.
Preço da ação
$0.63963115
Última sincronização: 2026-08-26
Valor de mercado
$339.16M
Variação (1 dia)
0.00%
Variação (1 ano)
-35.23%
País
CN
Negociar Jiangsu Recbio Technology Co., Ltd. (2179)

Categoria

Healthcare
Histórico de dividendos de Jiangsu Recbio Technology Co., Ltd. (2179)
Jiangsu Recbio Technology Co., Ltd. (símbolo da ação: 2179) realizou um total de 0 pagamentos de dividendos.
A soma de todos os dividendos (ajustada para desdobramentos de ações) é: 0.00
Rendimento de dividendos (TTM): 0
Pagamentos de dividendos de Jiangsu Recbio Technology Co., Ltd. (2179) de 2026 a 2026
Pagamentos anuais de dividendos
Ano Dividendo (ajustado para desdobramentos) Alterar
Não há dados suficientes para as datas fornecidas.
Lista de todos os pagamentos de dividendos
Ano Dividendo Alterar
Não há dados suficientes para as datas fornecidas.
Dividendos de empresas semelhantes ou concorrentes
Empresa Número de pagamentos de dividendos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH